8-K: TC BioPharm Announces Second Acquisition Letter of Intent, Expanding CAR-T Therapy Platform

TC BioPharm has entered into a non-binding letter of intent to acquire a private biotech company focused on innovative CAR-T therapies, marking their second such agreement in recent months.

Summary

• TC BioPharm has signed a non-binding letter of intent to acquire a private biotechnology company specializing in CAR-T therapies.
• The acquisition target has demonstrated proof-of-concept data for treating various solid tumors, including colorectal, pancreatic, mesothelioma, ovarian, and breast cancer.
• The deal involves a cash payment of $20 million, less any seller debt, and the issuance of American Depository Shares (ADS) valued at $20 million, based on the average price of a recent capital raise exceeding $50 million.
• The seller will also receive milestone payments upon achieving certain development goals.
• The transaction is subject to due diligence, definitive agreements, securing adequate financing, and regulatory approvals.
• There is no guarantee that the transaction will be completed on the proposed terms or at all.

Sentiment

Score: 7

Explanation: The announcement is positive due to the potential expansion of the company's therapeutic platform and pipeline, but the non-binding nature of the agreement and the need for financing introduce some uncertainty.

Positives

• The acquisition will expand TC BioPharm's therapeutic platform into CAR-T therapies.
• The target company has demonstrated pre-clinical proof of concept data for its CAR-T candidate in multiple solid tumors.
• The acquisition will provide synergies in CAR development expertise, gamma delta and alpha beta T-cells.
• The combined entity will have an expanded asset base and a strong patent portfolio.
• The acquisition could lead to multiple data inflection points in 2024 and 2025.

Negatives

• The letter of intent is non-binding, and there is no guarantee that the acquisition will be completed.
• The transaction is subject to several contingencies, including due diligence, definitive agreements, financing, and regulatory approvals.
• The timing and aggregate consideration may differ from what is currently contemplated.

Risks

• The proposed transaction may not be completed on the terms contemplated or at all.
• The timing of closing and the aggregate consideration may materially differ from the current plan.
• The company needs to secure adequate financing to complete the acquisition.
• The company needs to obtain all necessary third-party and governmental approvals.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates potential data inflection points in several pipeline assets in a variety of indications in 2024 and 2025, contingent on the successful completion of the acquisition and continued development.

Management Comments

• Management is extremely pleased to announce this second potential acquisition which will provide strong advantages to our current therapeutic platform as well as expand our efforts into autoimmune disease.
• There are substantial synergies between the two companies with extensive benefits to the business combination including CAR development expertise as well as gamma delta and alpha beta T-cells.
• Our existing expertise in gamma delta T-cells as well as transitioning processes and therapeutics from autologous to allogeneic will be impactful in advancing the solid tumor assets of the acquisition.
• The acquired company brings strong CAR engineering expertise to help us further develop our co-stimulatory CAR as well as a strong clinical team.
• We believe that the combination of these two companies provides a well balanced platform for investors and patients in our pursuit of creating next-generation cell therapies for the treatment of multiple indications.
• This represents not only multiple shots on goal, but an expanded asset base in several immune responder cells for the treatment of a wide range of disease with an extensive patent portfolio.
• I am proud of our ability to navigate a difficult capital market environment and identify complimentary resources that will continue to enhance the overall value of our company and look forward to working with our expanded team.

Industry Context

This announcement reflects a broader trend in the biotechnology industry where companies are actively pursuing mergers and acquisitions to expand their therapeutic platforms and pipelines, particularly in the rapidly evolving field of cell therapies.

Comparison to Industry Standards

• The acquisition of a CAR-T focused company is consistent with the industry trend of companies seeking to expand their capabilities in this promising area of cancer treatment.
• Companies like Kite Pharma (acquired by Gilead) and Juno Therapeutics (acquired by Celgene) have demonstrated the value of CAR-T technology, making it a sought-after asset.
• TC BioPharm's focus on allogeneic therapies aligns with the industry's push to develop more accessible and scalable cell therapies, similar to companies like Allogene Therapeutics.
• The pre-clinical proof of concept data for the target company's CAR-T candidate is a positive sign, but will need to be validated in clinical trials, similar to the development path of other CAR-T therapies.

Stakeholder Impact

• Shareholders may view the acquisition positively due to the potential for growth and expanded pipeline.
• Employees of both companies may experience changes in roles and responsibilities.
• Customers and patients may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the financial aspects of the transaction.

Next Steps

• Complete due diligence on the acquisition target.
• Negotiate and execute definitive agreements.
• Secure adequate financing for the transaction.
• Obtain all necessary third-party and governmental approvals.
• Integrate the acquired company's assets and personnel.

Key Dates

Keywords

CAR-T therapy, acquisition, biotechnology, solid tumors, gamma-delta T cells, allogeneic, autoimmune diseases, M&A, cell therapies